The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers.

ABSTRACT: Kirsten rat sarcoma (KRAS) is a small GTPase which acts as a molecular switch to regulate several cell biological processes including cell survival, proliferation, and differentiation. Alterations in KRAS have been found in 25% of all human cancers, with pancreatic cancer (90%), colorectal cancer (45%), and lung cancer (35%) being the types of cancer with the highest mutation rates. KRAS oncogenic mutations are not only responsible for malignant cell transformation and tumor development but also related to poor prognosis, low survival rate, and resistance to chemotherapy. Although different strategies have been developed to specifically target this oncoprotein over the last few decades, almost all of them have failed, relying on the current therapeutic solutions to target proteins involved

SUBMITTER: Andrade F 

PROVIDER: S-EPMC10302894 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature